Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2014 | Pages:
538 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2014', provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 8 List of Figures 10 Introduction 11 Global Markets Direct Report Coverage 11 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview 12 Therapeutics Development 13 Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview 13 Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis 14 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies 15 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes 22 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance 25 Late Stage Products 25 Clinical Stage Products 26 Early Stage Products 27 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies 28 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes 35 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development 37 Bristol-Myers Squibb Company 37 Johnson & Johnson 38 Amgen Inc. 39 Sanofi 40 AstraZeneca PLC 41 GlaxoSmithKline plc 42 Seattle Genetics, Inc. 43 MedImmune, LLC 44 medac GmbH 45 Merck & Co., Inc. 46 Gamida Cell Ltd. 47 Piramal Enterprises Limited 48 Bio-Path Holdings, Inc. 49 Millennium Pharmaceuticals, Inc. 50 Novartis AG 51 Pfizer Inc. 52 Sigma-Tau S.p.A. 53 Onyx Pharmaceuticals, Inc. 54 4SC AG 55 Immunomedics, Inc. 56 DiNonA Inc. 57 Ariad Pharmaceuticals, Inc. 58 Jazz Pharmaceuticals plc 59 Portola Pharmaceuticals, Inc. 60 Pharmacyclics, Inc. 61 MorphoSys AG 62 Threshold Pharmaceuticals, Inc. 63 Synta Pharmaceuticals Corp. 64 Sareum Holdings plc 65 SymBio Pharmaceuticals Limited 66 Spectrum Pharmaceuticals, Inc. 67 Affimed Therapeutics AG 68 Ambit Biosciences Corporation 69 Actinium Pharmaceuticals, Inc. 70 Priaxon AG 71 Erytech Pharma SA 72 Celator Pharmaceuticals, Inc. 73 Cellectis S.A. 74 CanBas Co., Ltd. 75 Deciphera Pharmaceuticals, LLC 76 NovImmune SA 77 Stemline Therapeutics, Inc. 78 Effimune SAS 79 Kainos Medicine, Inc. 80 Polyphor Ltd. 81 Syndax Pharmaceuticals, Inc. 82 Fate Therapeutics, Inc. 83 Mirna Therapeutics, Inc. 84 Omeros Corporation 85 SBI Biotech Co., Ltd. 86 Kiadis Pharma B.V. 87 Sigma-Tau Pharmaceuticals, Inc 88 Interprotein Corporation 89 EpiZyme, Inc. 90 NuCana BioMed Limited 91 Pfenex Inc. 92 Otsuka Holdings Co., Ltd. 93 Eureka Therapeutics, Inc. 94 Bexion Pharmaceuticals, LLC. 95 Karyopharm Therapeutics, Inc. 96 Kite Pharma, Inc. 97 Verastem, Inc. 98 Verastem, Inc. 98 Jasco Pharmaceuticals, LLC. 99 The International Biotechnology Center (IBC) "Generium" 100 Evgen Limited 101 ARA Healthcare Pvt. Ltd. 102 Cantargia AB 103 Tolero Pharmaceuticals, Inc. 104 Ceronco Biosciences 105 AbbVie Inc. 106 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment 107 Assessment by Monotherapy Products 107 Assessment by Combination Products 108 Assessment by Target 109 Assessment by Mechanism of Action 114 Assessment by Route of Administration 119 Assessment by Molecule Type 121 Drug Profiles 124 pegaspargase - Drug Profile 124 ponatinib - Drug Profile 126 asparaginase - Drug Profile 128 StemEx - Drug Profile 129 blinatumomab - Drug Profile 131 asparaginase - Drug Profile 134 vincristine sulfate - Drug Profile 136 inotuzumab ozogamicin - Drug Profile 139 Recombinant Asparaginase - Drug Profile 141 calaspargase pegol - Drug Profile 142 entinostat - Drug Profile 143 ixazomib citrate - Drug Profile 147 MK-2206 - Drug Profile 150 moxetumomab pasudotox - Drug Profile 153 brentuximab vedotin - Drug Profile 155 ponatinib - Drug Profile 160 ibrutinib - Drug Profile 162 ATIR - Drug Profile 167 (cytarabine + daunorubicin hydrochloride) - Drug Profile 169 INNO-305 - Drug Profile 171 MOR-208 - Drug Profile 172 epratuzumab - Drug Profile 174 tisagenlecleucel-T - Drug Profile 179 erismodegib - Drug Profile 181 asparaginase - Drug Profile 184 Cell Therapy to Target CD20 for Chemotherapy Resistant Cancers - Drug Profile 185 Cell Therapy to Target CD19 for Oncology - Drug Profile 186 veltuzumab - Drug Profile 187 nilotinib - Drug Profile 190 moxetumomab pasudotox - Drug Profile 193 trametinib dimethyl sulfoxide - Drug Profile 195 AT-9283 - Drug Profile 198 asparaginase - Drug Profile 200 binimetinib - Drug Profile 202 ruxolitinib phosphate - Drug Profile 206 OVI-123 - Drug Profile 210 rigosertib sodium - Drug Profile 211 ALT-803 - Drug Profile 215 birinapant - Drug Profile 217 BPX-501 - Drug Profile 219 Cell Therapy to Inhibit CD19 for Oncology - Drug Profile 221 Cell Therapy for Acute Lymphocytic Leukemia - Drug Profile 222 DFP-10917 - Drug Profile 223 Cell Therapy Targeting CD25 for ALL and AML - Drug Profile 224 Cell Therapy Targeting CD19 for ALL - Drug Profile 225 Minor Histocompatibility Antigen - Drug Profile 226 pevonedistat hydrochloride - Drug Profile 227 SGN-CD19A - Drug Profile 229 panobinostat - Drug Profile 230 4SC-202 - Drug Profile 236 SAR-650984 - Drug Profile 238 carfilzomib - Drug Profile 240 everolimus - Drug Profile 244 ganetespib - Drug Profile 248 TH-302 - Drug Profile 252 (cytarabine + daunorubicin hydrochloride) - Drug Profile 259 quizartinib - Drug Profile 261 AFM-11 - Drug Profile 263 Cell Therapy to Target CD19 for Cancer - Drug Profile 264 PF-03084014 - Drug Profile 266 BP-100-1.01 - Drug Profile 267 rebastinib tosylate - Drug Profile 269 GNKG-168 - Drug Profile 271 MRX-34 - Drug Profile 273 ilorasertib - Drug Profile 275 Vaccine to Target WT1 for Oncology - Drug Profile 277 OPB-51602 - Drug Profile 278 BMS-906024 - Drug Profile 280 FT-1050 - Drug Profile 281 P-2745 - Drug Profile 283 VS-4718 - Drug Profile 284 selinexor - Drug Profile 285 Sulforadex - Drug Profile 288 Iomab-B - Drug Profile 289 EPZ-5676 - Drug Profile 291 KTE-C19 CAR - Drug Profile 292 Cell Therapy for Oncology - Drug Profile 294 CB-839 - Drug Profile 295 JZP-416 - Drug Profile 296 AZD-6738 - Drug Profile 298 Cell Therapy for Leukemia - Drug Profile 299 ABL-001 - Drug Profile 301 HDM-201 - Drug Profile 302 Cell Therapy for Acute Lymphoblastic Leukemia - Drug Profile 303 DNP-001 - Drug Profile 304 daratumumab - Drug Profile 305 SyB-0702 - Drug Profile 307 MD-707 - Drug Profile 308 CBS-9106 - Drug Profile 309 Aurora Kinase + FLT3 Kinase Programme for Oncology - Drug Profile 311 ARABS-1 - Drug Profile 312 IPC-003 - Drug Profile 313 Mab81.2 - Drug Profile 314 Lenaldekar - Drug Profile 316 TP-0903 - Drug Profile 317 BXQ-350 - Drug Profile 318 BLyS-gel - Drug Profile 320 PRT-060318 - Drug Profile 321 UNC-569 - Drug Profile 322 UCART-19 - Drug Profile 324 Small Molecule to Inhibit Mer Receptor Tyrosine Kinase for Oncology - Drug Profile 325 Monoclonal Antibody to Inhibit Tyrosine-Protein Kinase Mer for Oncology - Drug Profile 326 Small Molecule for Oncology - Drug Profile 327 GNR-022 - Drug Profile 328 MSK-777 - Drug Profile 329 NUC-5435 - Drug Profile 330 pegaspargase biosimilar - Drug Profile 331 Drugs to Inhibit Gamma-Secretase for Acute Lymphocytic Leukemia - Drug Profile 332 BMS-871 - Drug Profile 333 KM-101 - Drug Profile 334 VS-6062 - Drug Profile 335 NM-814 - Drug Profile 336 NM-869 - Drug Profile 338 Cell Therapy for Acute Lymphoblastic Leukemia - Drug Profile 339 449-PXN-4017 - Drug Profile 340 Monoclonal Antibody to Inhibit BAFF-R for B Acute Lymphoblastic Leukemia - Drug Profile 341 ESK-BiTE - Drug Profile 342 PF-114 - Drug Profile 344 Cell Therapy to Target Tslpr for Acute Lymphoblastic Leukemia - Drug Profile 345 UNC-1062 - Drug Profile 346 asparaginase nanoparticle - Drug Profile 348 mitoxantrone hydrochloride liposomal - Drug Profile 349 Monoclonal Antibody to Target ROR-1 for Leukemias - Drug Profile 350 SL-101 - Drug Profile 351 Small Molecules to Inhibit TYK2 for Neurology, Gastrointestinal, Immunology and Oncology - Drug Profile 352 Small Molecule to Antagonize P2Y8 for Acute Lymphoblastic Leukemia - Drug Profile 353 NI-1701 - Drug Profile 354 Small Molecules to Inhibit Tyk2 for Inflammatory Diseases and Cancer - Drug Profile 355 JP-11646 - Drug Profile 356 hA19 Antibody - Drug Profile 357 Small Molecules to Inhibit MDM2 for Oncology - Drug Profile 358 Small Molecules to Inhibit JAK for Oncology and Hematological Disorders - Drug Profile 359 POL-5551 - Drug Profile 360 Small Molecules to Inhibit CRLF-2 for ALL - Drug Profile 362 KM-201 - Drug Profile 363 Small Molecules for T-Cell Acute Lymphoblastic Leukemia - Drug Profile 364 Drug Targeting CD22 for B-Precursor Acute Lymphoblastic Leukemia - Drug Profile 365 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Recent Pipeline Updates 366 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects 515 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products 516 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones 517 Featured News & Press Releases 517 Appendix 527 Methodology 527 Coverage 527 Secondary Research 527 Primary Research 527 Expert Panel Validation 527 Contact Us 528 Disclaimer 528
List of Tables Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H2 2014 23 Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis, H2 2014 24 Number of Products under Development by Companies, H2 2014 26 Number of Products under Development by Companies, H2 2014 (Contd..1) 27 Number of Products under Development by Companies, H2 2014 (Contd..2) 28 Number of Products under Development by Companies, H2 2014 (Contd..3) 29 Number of Products under Development by Companies, H2 2014 (Contd..4) 30 Number of Products under Development by Companies, H2 2014 (Contd..5) 31 Number of Products under Investigation by Universities/Institutes, H2 2014 33 Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 34 Comparative Analysis by Late Stage Development, H2 2014 35 Comparative Analysis by Clinical Stage Development, H2 2014 36 Comparative Analysis by Early Stage Development, H2 2014 37 Products under Development by Companies, H2 2014 38 Products under Development by Companies, H2 2014 (Contd..1) 39 Products under Development by Companies, H2 2014 (Contd..2) 40 Products under Development by Companies, H2 2014 (Contd..3) 41 Products under Development by Companies, H2 2014 (Contd..4) 42 Products under Development by Companies, H2 2014 (Contd..5) 43 Products under Development by Companies, H2 2014 (Contd..6) 44 Products under Investigation by Universities/Institutes, H2 2014 45 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 46 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H2 2014 47 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Johnson & Johnson, H2 2014 48 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Amgen Inc., H2 2014 49 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sanofi, H2 2014 50 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AstraZeneca PLC, H2 2014 51 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by GlaxoSmithKline plc, H2 2014 52 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Seattle Genetics, Inc., H2 2014 53 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by MedImmune, LLC, H2 2014 54 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by medac GmbH, H2 2014 55 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Merck & Co., Inc., H2 2014 56 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Gamida Cell Ltd., H2 2014 57 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Piramal Enterprises Limited, H2 2014 58 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bio-Path Holdings, Inc., H2 2014 59 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 60 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Novartis AG, H2 2014 61 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfizer Inc., H2 2014 62 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sigma-Tau S.p.A., H2 2014 63 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 64 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H2 2014 65 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Immunomedics, Inc., H2 2014 66 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by DiNonA Inc., H2 2014 67 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2014 68 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Jazz Pharmaceuticals plc, H2 2014 69 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Portola Pharmaceuticals, Inc., H2 2014 70 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pharmacyclics, Inc., H2 2014 71 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by MorphoSys AG, H2 2014 72 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H2 2014 73 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Synta Pharmaceuticals Corp., H2 2014 74 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sareum Holdings plc, H2 2014 75 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by SymBio Pharmaceuticals Limited, H2 2014 76 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2014 77 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Affimed Therapeutics AG, H2 2014 78 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ambit Biosciences Corporation, H2 2014 79 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 80 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Priaxon AG, H2 2014 81 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Erytech Pharma SA, H2 2014 82 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Celator Pharmaceuticals, Inc., H2 2014 83 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellectis S.A., H2 2014 84 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by CanBas Co., Ltd., H2 2014 85 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 86 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NovImmune SA, H2 2014 87 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Stemline Therapeutics, Inc., H2 2014 88 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Effimune SAS, H2 2014 89 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kainos Medicine, Inc., H2 2014 90 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Polyphor Ltd., H2 2014 91 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Syndax Pharmaceuticals, Inc., H2 2014 92 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Fate Therapeutics, Inc., H2 2014 93 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Mirna Therapeutics, Inc., H2 2014 94 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Omeros Corporation, H2 2014 95 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by SBI Biotech Co., Ltd., H2 2014 96 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kiadis Pharma B.V., H2 2014 97 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H2 2014 98 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Interprotein Corporation, H2 2014 99 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by EpiZyme, Inc., H2 2014 100 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NuCana BioMed Limited, H2 2014 101 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfenex Inc., H2 2014 102 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Otsuka Holdings Co., Ltd., H2 2014 103 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Eureka Therapeutics, Inc., H2 2014 104 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bexion Pharmaceuticals, LLC., H2 2014 105 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 106 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kite Pharma, Inc., H2 2014 107 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Verastem, Inc., H2 2014 108 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Jasco Pharmaceuticals, LLC., H2 2014 109 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by The International Biotechnology Center (IBC) �Generium�, H2 2014 110 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Evgen Limited, H2 2014 111 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ARA Healthcare Pvt. Ltd., H2 2014 112 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cantargia AB, H2 2014 113 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Tolero Pharmaceuticals, Inc., H2 2014 114 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ceronco Biosciences, H2 2014 115 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AbbVie Inc., H2 2014 116 Assessment by Monotherapy Products, H2 2014 117 Assessment by Combination Products, H2 2014 118 Number of Products by Stage and Target, H2 2014 121 Number of Products by Stage and Mechanism of Action, H2 2014 126 Number of Products by Stage and Route of Administration, H2 2014 130 Number of Products by Stage and Molecule Type, H2 2014 133 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics - Recent Pipeline Updates, H2 2014 376 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, H2 2014 525 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products, H2 2014 526
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
